PHASE-II STUDY OF PROTRACTED INFUSIONAL 5-FLUOROURACIL COMBINED WITH CISPLATINUM FOR ADVANCED GASTRIC-CANCER - REPORT FROM THE JAPAN CLINICAL ONCOLOGY GROUP (JCOG)

被引：56

作者：

OHTSU, A

SHIMADA, Y

YOSHIDA, S

SAITO, H

SEKI, S

MORISE, K

KURIHARA, M

机构：

[1] NATL CANC CTR,DEPT INTERNAL MED,TOKYO 104,JAPAN

[2] YAMAGATA PREFECTURAL CENT HOSP,DEPT INTERNAL MED,YAMAGATA,JAPAN

[3] SAKU CENT HOSP,DEPT INTERNAL MED,NAGANO,JAPAN

[4] NAGOYA UNIV,DEPT INTERNAL MED 1,NAGOYA,AICHI,JAPAN

[5] SHOWA UNIV,TOYOSU HOSP,DEPT GASTROENTEROL,TOKYO,JAPAN

来源：

EUROPEAN JOURNAL OF CANCER | 1994年 / 30A卷 / 14期

关键词：

GASTRIC CANCER; CHEMOTHERAPY; 5-FLUOROURACIL; CISPLATINUM;

D O I：

10.1016/0959-8049(94)00350-E

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A phase II study of protracted infusional 5-fluorouracil (5FU) combined with cisplatin (CDDP) was conducted in patients with advanced gastric carcinoma. 55 previously untreated patients, including 40 patients with measurable disease, were treated with 5FU (800 mg/m(2), days 1-5, protracted infusion) and CDDP (20 mg/m(2), days 1-5, drip infusion). Objective tumour responses were observed in 17/40 (43%) patients with measurable disease. Median survival was 7 months. WHO grade 3 or 4 leucopenia occurred in 10/55 patients (18%) and grade 3/4 thrombocytopenia was observed in 4 patients (7%). A randomised trial including this regimen is now underway in a JCOG study.

引用

收藏

页码：2091 / 2093

页数：3

相关论文

共 16 条

[1] A PHASE-II STUDY OF CISPLATIN IN ADVANCED GASTRIC-CANCER [J].

BEER, M ;

COCCONI, G ;

CECI, G ;

VARINI, M ;

CAVALLI, F .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (06) :717-720

[2] FAMTX VERSUS ETOPOSIDE, DOXORUBICIN, AND CISPLATIN - A RANDOM ASSIGNMENT TRIAL IN GASTRIC-CANCER [J].

KELSEN, D ;

ATIQ, OT ;

SALTZ, L ;

NIEDZWIECKI, D ;

GINN, D ;

CHAPMAN, D ;

HEELAN, R ;

LIGHTDALE, C ;

VINCIGUERRA, V ;

BRENNAN, M .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :541-548

[3]

KIM NK, 1993, CANCER, V71, P3813, DOI 10.1002/1097-0142(19930615)71:12<3813::AID-CNCR2820711205>3.0.CO

[4]

2-5

[5] CHEMOTHERAPEUTIC PROTOCOL IN THE TREATMENT OF METASTASIZING GASTRIC-CARCINOMA - METHOTREXATE, ADRIAMYCIN AND 5-FLUOROURACIL [J].

KLEIN, HO ;

WICKRAMANAYAKE, PD ;

DIETERLE, F ;

MOHR, R ;

OERKERMANN, H ;

BROCK, J ;

BEYER, D ;

GROSS, R .

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1982, 107 (45) :1708-1712

[6] COMBINATION CHEMOTHERAPY WITH CISPLATIN AND 5-FLUOROURACIL 5-DAY INFUSION IN THE THERAPY OF ADVANCED GASTRIC-CANCER - A PHASE-II TRIAL [J].

LACAVE, AJ ;

BARON, FJ ;

ANTON, LM ;

ESTRADA, E ;

DESANDE, LMG ;

PALACIO, I ;

ESTEBAN, E ;

GRACIA, JM ;

BUESA, JM ;

FERNANDEZ, OA ;

BARON, MG .

ANNALS OF ONCOLOGY, 1991, 2 (10) :751-754

[7] ETOPOSIDE, DOXORUBICIN, AND CISPLATIN CHEMOTHERAPY FOR ADVANCED GASTRIC ADENOCARCINOMA - RESULTS OF A PHASE-II TRIAL [J].

LERNER, A ;

GONIN, R ;

STEELE, GD ;

MAYER, RJ .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :536-540

[8] PILOT PHASE-II STUDY OF CIS-DIAMMINEDICHLOROPLATINUM(II) AGAINST METASTATIC GASTRIC CANCERS [J].

MIYAMOTO, K ;

YOSHIDA, S ;

SAITO, D ;

SHIMADA, Y ;

TAJIRI, H ;

YAMAGUCHI, H ;

OHKURA, H ;

YOSHINO, M ;

YOSHIDA, T ;

OKAZAKI, N ;

YOSHIMORI, M ;

HIJIKATA, A .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1990, 20 (02) :169-176

[9] A PHASE-II STUDY OF COMBINED 5-FLUOROURACIL, DOXORUBICIN, AND CISPLATIN IN THE TREATMENT OF ADVANCED UPPER GASTROINTESTINAL ADENOCARCINOMAS [J].

MOERTEL, CG ;

RUBIN, J ;

OCONNELL, MJ ;

SCHUTT, AJ ;

WIEAND, HS .

JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (07) :1053-1057

[10]

MOERTEL CG, 1977, RECENT ADV CANCER TR, P311